The monoclonal antibody dupilumab markedly reduces itch and the number of skin lesions in previously treated patients with severe prurigo nodularis, suggest results from a phase 2 trial.
/PRNewswire/ Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (oral.
Trevi Therapeutics Announces Second Quarter 2022 Financial Results and Business Update businessinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from businessinsider.com Daily Mail and Mail on Sunday newspapers.